Alan W. Dunton, M.D.
President and Chief Executive Officer

Graham P. Allaway, Ph.D.
Chief Operating Officer

Jane Pritchett Henderson
Chief Financial and Business Officer

Tom Lategan, D.Phil.
Vice President of Regulatory Affairs

David E. Martin, Pharm.D., MBA
Sr. Vice President, Drug Development

Scott McCallister, M.D.
Chief Medical Officer

John D. Richards, D.Phil.
Vice President, Manufacturing Operations

Frederick Schmid, DVM, MBA  
Senior Vice President, Commercial Operations and Business Development

Alan W. Dunton, M.D.  has served as our Chief Executive Officer since January 2007 and our president since July 2007.  Since 2005, Dr. Dunton has served as the non-executive chairman of the board of directors of ActivBiotics, Inc., a privately held biopharmaceutical company. Previously, he was the president and chief executive officer of Metaphore Pharmaceuticals, Inc. from 2003 until 2005, when it merged with ActivBiotics. From 2004 until 2005, Dr. Dunton served as a member of the board of directors of Vicuron Pharmaceuticals until it was acquired by Pfizer, Inc. In 2002, Dr. Dunton served as president, chief operating officer and a director of Emisphere Technologies, Inc., a biopharmaceutical company. From 1994 to 2001, Dr. Dunton was a senior executive in various capacities in the Pharmaceuticals Group of Johnson & Johnson. From 1999 to 2001, Dr. Dunton was president and managing director of The Janssen Research Foundation, a Johnson & Johnson company. From 1998 to 1999, he served as group vice president of global clinical research and development of Janssen. Prior to joining Janssen, Dr. Dunton was vice president of global clinical research and development at the R.W. Johnson Pharmaceutical Research Institute, also a Johnson & Johnson company. Prior to joining Johnson & Johnson, Dr. Dunton held positions in clinical research and development at Syntex Corporation, CIBA-GEIGY Corporation and Hoffmann La Roche Inc.  Dr. Dunton also presently serves as a member of the board of directors of the following public companies: Targacept, Inc.; Adams Respiratory Therapeutics, Inc.; and MediciNova, Inc.  Dr. Dunton holds a M.D. degree from New York University School of Medicine, where he completed his residency in internal medicine. He also was a Fellow in Clinical Pharmacology at the New York Hospital/Cornell University Medical Center.

Graham P. Allaway, Ph.D.  has served as Panacos’ Chief Operating Officer since May 3, 2005. Prior to the merger between V.I. Technologies and the former (private) Panacos in March 2005, Dr. Allaway was Chief Operating Officer of the former Panacos. He was founding Chief Executive Officer and President of the former Panacos on its formation in 1999. Prior to founding the former Panacos, Dr. Allaway was Senior Vice-President for Drug Discovery at Boston Biomedica Inc., which he joined in 1998. Prior to this, Dr. Allaway was Chief Executive Officer of Manchester Biotech (United Kingdom) from 1997 to 1998. From 1990 to 1997, Dr. Allaway held various positions at Progenics Pharmaceuticals, Inc. in Tarrytown, New York. Dr. Allaway received his M.A. in Zoology from Oxford University and his Ph.D. in Virology from the University of London. He then held research fellowships at Memorial University in Newfoundland, Canada and at the National Institutes of Health in Bethesda, Maryland before entering industry.

Jane Pritchett Henderson has served as Panacos' Chief Financial and Business Officer since January 2008.  Before joining Panacos, Ms. Henderson was at HSBC Securities (USA), where she served as Managing Director – Head of Biopharmaceuticals. From February 2001 to February 2005, Ms. Henderson was a Managing Director at CIBC World Markets. From July 1999 to February 2001, Ms. Henderson was a Senior Vice President at Lehman Brothers. Prior to July 1999, Ms. Henderson held senior investment banking positions at Citigroup (formerly Salomon Smith Barney, Salomon Brothers), SG Warburg (now UBS), and Lehman Brothers. Ms. Henderson holds a BS in Psychology from Duke University.

Tom Lategan, D.Phil. has served as our Vice President of Regulatory Affairs since February 2007. Before joining Panacos, Dr. Lategan was Vice President, Regulatory Affairs for Actelion Pharmaceuticals US Inc. In this role, he was responsible for the regulatory strategy for Actelion's development products and projects. While at Actelion, Dr. Lategan compiled and submitted the successful New Drug Application (NDA) for TRACLEER in the U.S. and Canada, and managed subsequent interaction with the FDA, including panel review, package insert negotiation, and promotional material review. Also at Actelion, he drove the approval of ZAVESCA in the U.S. after an unsuccessful application by a previous sponsor. Prior to Actelion, Dr. Lategan was Vice President, Regulatory Affairs at The Medicines Company, where he was responsible for the NDA and other regulatory submissions for ANGIOMAX in the U.S., E.U., and Canada. Earlier in his career, Dr. Lategan held positions of increasing responsibility in regulatory and clinical product information at Roche. Dr. Lategan received his education in the United Kingdom. His doctorate in Pharmacology is from the University of Oxford and his bachelor's degree is from the University of Aberdeen.

David E. Martin, Pharm.D., MBA has served as our Senior Vice President, Drug Development since the merger between V.I. Technologies and the former Panacos in March 2005. Prior to the merger, Dr. Martin was the Senior Vice President, Drug Development of the former (private) Panacos since 2001. Prior to joining the former Panacos, Dr. Martin held the positions of Director, Clinical Pharmacology and Associate Director, Clinical Pharmacology at Bristol-Myers Squibb (formerly Dupont Pharmaceuticals), which he joined in 1999. Prior to this, Dr. Martin was Assistant Director, Virology Clinical Development at PharmaResearch Corporation from 1997 to 1999. From 1994 to 1997, Dr. Martin held various positions at SmithKline Beecham Pharmaceuticals. Dr. Martin received his Doctor of Pharmacy from the University of Southern California, then completed his Residency at USC School of Pharmacy and a Fellowship at The University of North Carolina at Chapel Hill and Glaxo, Inc. Dr. Martin received his Masters of Business Administration in Pharmaceutical Marketing from St. Joseph’s University.

Scott McCallister, M.D. has served as our Chief Medical Officer since October, 2006.  Before joining Panacos, Dr. McCallister was Director of Virology, Global Medical Affairs at Bristol-Myers Squibb from 2005-2006,  responsible for REYATAZ Phase IV global medical strategy along with  review and approval of all HIV-related study protocols. Prior to this, Dr. McCallister was with Boehringer Ingelheim Pharmaceuticals (BI) from 2000-2005 as international medical leader for development of the HIV protease inhibitor APTIVUS.  In this role at BI, he conducted nearly 30 Phase I-III clinical studies, served as lead medical author for the APTIVUS NDA and MAA (approved in US and EU, 2005), and was the primary spokesperson at the FDA Antiviral Drug Advisory Committee hearing.  Prior to joining industry, Dr. McCallister was boarded in Infectious Diseases and Internal Medicine, served as an Assistant Clinical Professor at Rush Medical College and was Medical Director of the Howard Brown Health Center in Chicago (a low-cost clinic for indigent patients).   He received his Bachelors degree from UCLA and his medical degree from St. George's University.

John D. Richards, D.Phil.  has served as Panacos’ Vice President, Manufacturing Operations since February 2006.  Prior to joining Panacos, Dr. Richards was a Vice President at The Medicines Company, with responsibility for product manufacturing and quality.  Since 1997 he was a key member of The Medicines Company’s management team that developed and launched ANGIOMAX in the US and oversaw the release and distribution of the drug in 35 countries internationally.   From 1993 until he joined The Medicines Company in October 1997, Dr. Richards was Director of Process Development and Manufacturing at Immulogic Pharmaceutical Corporation. From 1989 to 1993, Dr. Richards was a Technical Manager at Zeneca PLC, a pharmaceutical company, where he developed and implemented processes for the manufacture of pharmaceutical active intermediates. In 1986, Dr. Richards helped establish Cambridge Research Biochemicals, a manufacturer of products for pharmaceutical and academic customers. Dr. Richards holds an M.A. and a D.Phil. in organic chemistry from the University of Oxford, United Kingdom, and has carried out post-doctoral research work at the Medical Research Council’s Laboratory of Molecular Biology in Cambridge, United Kingdom.

Frederick Schmid, DVM, MBA has served as our Senior Vice President, Commercial Operations and Business Development, since May of 2006.  Dr. Schmid has held leadership positions in HIV sales and marketing since 1997, most recently as Vice President, Sales and Marketing for Virology/HIV at Roche Laboratories.  In this role, he was responsible for all aspects of Roche’s U.S. HIV franchise, leading a team of 135 sales and marketing personnel.    Prior to this role, Dr. Schmid was Executive Director of HIV Marketing at GlaxoSmithKline, with responsibility for business planning, business development, and all aspects of product marketing and reimbursement.  Dr. Schmid joined Glaxo in 1991 and held roles in sales and sales management, marketing, and global commercial strategy, primarily in the HIV and oncology areas.  Dr. Schmid holds a DVM from Iowa State University College of Veterinary Medicine and an MBA from The University of North Carolina at Chapel Hill.